HiberCell is the first company exclusively focused on tumor dormancy detection and therapeutics. The company is developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers, with the ultimate goal of preventing cancer relapse and metastasis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/07/19 | $60,750,000 | Series A |
ARCH Venture Partners | undisclosed |
